Clinical Trial Update: MK-2206 and AZD6244 in Patients With Advanced Colorectal Carcinoma [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluating the combination of MK-2206 and AZD6244 in advanced colorectal carcinoma has completed, with results posted in December 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Neoplasms

Drugs mentioned

• AZD6244 (selumetinib)
• MK-2206 (MK-2206)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Colorectal Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2014-12-04